D
iabetes mellitus is the most common metabolic disorder in worldwide populations. The risk for developing cardiovascular complications is increased by 2-to 6-fold in diabetic subjects. 1 Disorders in lipid metabolism, coagulation, and fibrinolysis have been implicated in the development of diabetic vascular complications. 2 It is generally accepted that hemostasis is determined by a balance between coagulation and fibrinolysis. Imbalance between the two antagonistic systems may result in thrombosis or hemorrhage. Plasmin, the active product of the fibrinolytic system, functions by dissolving fibrin clots and maintains the fluidity of blood. 3 The generation of plasmin is regulated by plasminogen activators and their inhibitors. tPA is the main activator for plasminogen in the blood circulation. 4 The activity of tPA is modulated by its major physiological inhibitor, PAI-1. 5 The levels of PAI-1 mRNA are significantly increased in atherosclerotic vessels and are correlated with the severity of atherosclerotic lesions. 6 An increase in PAI-1 production or a decrease in tPA generation from vascular ECs may reduce fibrinolytic activity in the blood. Attenuated fibrinolytic activity or reduced fibrinolytic response to ischemic stimulus has been found in diabetic subjects. 2, 7 Vascular ECs synthesize both PAI-1 and tPA. The generation of PAI-1 or tPA from ECs is regulated by a variety of biological agonists, including plasma lipoproteins. The release of PAI-1 from ECs has been increased by treatments with VLDLs isolated from hypertriglyceridemic individuals. 8 LDLs and their oxidized forms, modified by acetylation, UV radiation, or CuSO 4 , stimulate the production of PAI-1 in ECs. 9 -11 Lp(a), an LDL-like lipoprotein, stimulates PAI-1 production in ECs, and oxidization amplifies the effect of Lp(a). 12, 13 Treatment with native LDL reduces the generation of tPA in ECs.
14 Glycated LDLs are susceptible to oxidization in vitro. 15 Increased levels of glycated LDLs have been detected in subjects with poorly controlled diabetes. 16, 17 The influence of glycated lipoproteins on the production of fibrinolytic regulators in vascular ECs has not been documented. The present study examined the effect of glycation on LDL-induced generation of PAI-1 and tPA from cultured human vascular ECs.
Methods

Isolation of Lipoproteins
LDL fractions (dϭ1.024 to 1.063 g/mL) were isolated from fresh human plasma of healthy donors by sequential floating ultracentrifugation. Lp(a) was removed from LDL by lysine-Sepharose CL 4B affinity chromatography as previously described. 18 Lp(a)-free LDLs were dialyzed at 4°C against 150 mmol/L NaCl and 0.01% EDTA (pH 7.4) and stored in sealed tubes overlaid with N 2 at 4°C in the dark. The levels of endotoxin in lipoproteins were monitored by the Limulus amebocyte lysate test using commercially available kits (E-TOXATE, Sigma Chemical Co). No detectable amount of endotoxin was found in lipoprotein preparations used in this study.
Modification of Lipoproteins
LDL preparations were diluted to 2 mg of protein per milliliter with 0.1 mol/L phosphate buffer (pH 7.4) containing 0.01% EDTA and 0.01% NaN 3 and then incubated with 5 to 200 mmol/L glucose and equimolar amounts of NaBH 3 CN for 1 to 3 weeks at 37°C in the dark under N 2 . Native LDLs were processed identically except without the addition of glucose. At the end of glycation, lipoproteins were dialyzed to remove free glucose. Radiolabeled [ 14 C]glucose (10 Ci/mL) was mixed with unlabeled glucose during glycation to monitor the incorporation of glucose. Oxidized LDLs were modified by 5 mol/L CuSO 4 at 22°C for 24 hours.
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Analysis of Amino Acid Profile of Lipoproteins
Glycated and native LDLs were hydrolyzed in 2N HCl for 24 hours at 100°C, washed with coupling buffer (acetonitrile/ethanol/triethylamine/ water, 10:5:2:3, vol/vol/vol/vol), and dried by evaporation. The samples were resuspended in 100 L of the coupling buffer containing 0.45 mol/L phenylisothiocyanate, incubated at room temperature for 5 minutes, and then dried. Residues were resuspended in 400 L of 70 mmol/L sodium acetate (pH 6.5) and analyzed on an Ultrasphere ODS C 18 column (4.6 mmϫ25 cm) using a gradient solvent system (0% to 30% acetonitrile, 100% to 70% of 70 mmol/L sodium acetate) on a high-performance liquid chromatography (Gold System, Beckman Instruments Inc) and monitored at 245 nm.
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Preparation of Glucitollysine
␣-N-Z-L-Lysine (Sigma) was incubated with 27 mmol/L glucose for 17 days in 0.2 mol/L sodium phosphate buffer (pH 8.0) as previously described. 20 The mixture was passed through a Dowex 50 WX8 column followed by a Sephadex G-15 column. The protecting group was removed by catalytic transfer hydrogenation.
Cell Culture and Experimental Incubation
HUVECs were obtained by collagenase digestion as previously described. 21 Cell type was verified by morphology and the presence of factor VIII antigen. Cells were grown in medium 199 supplemented with 10% heat-inactivated FBS, 30 g/mL of EC growth stimulator, 100 g/mL of heparin, 0.1 mmol/L nonessential amino acids, 200 U/mL of penicillin, and 200 g/mL of streptomycin in a humidified incubator under 95% air-5% CO 2 at 37°C. Confluent cells were incubated in heparin-free medium 199 with or without LDL.
Measurement of PAI-1 and tPA Antigen
Conditioned media of HUVECs were collected at the end of incubation. Cells were harvested in PBS (pH 7.4) containing 0.1% SDS and 0.5% Triton X-100. Total amounts of PAI-1 and tPA antigen (free and complex forms) in the media were estimated by using IMUBIND PAI-1 or tPA ELISA kits (American Diagnostica Inc). The levels of PAI-1 and tPA antigen were read on a microtest plate spectrophotometer at 490 nm and were expressed in micrograms of antigen per milligram of cellular proteins.
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Northern Blotting Analysis
Total cellular RNA was extracted from cells at the end of incubation by the guanidine isothiocyanate-CsCl method. 22 RNA was denatured, subjected to electrophoresis on a 1% agarose-formaldehyde gel, and then transferred to Zeta-Probe GT blotting membranes (Bio-Rad). Plasmid containing the cDNA fragment-encoded human tPA, PAI-1, 23 or ␤-actin was labeled with [ 32 P]dCTP (Ͼ111 TBq/ mmol/L, New England Nuclear) by using random-primer labeling kits. Blots were prehybridized in 0.25 mol/L Na 2 HPO 4 (pH 7.2) and 7% SDS for 10 minutes at 42°C and then hybridized with denatured probe for 16 hours at 42°C. 24 After hybridization, blots were washed and subjected to autoradiography. The levels of PAI-1 and tPA mRNA were quantified from autoradiogram by density scanning and then adjusted with ␤-actin mRNA on rehybridized blots.
Metabolic Labeling and Immunoprecipitation
Confluent cells in 60-mm dishes were treated with 100 Ci/mL of Tran 35 S label (38 TBq/mmol/L, 85% methionine, and 15% cystine, ICN) in methionine-and cystine-free supplemented with 2 mmol/L glutamine and 10% serum with or without lipoproteins as previously described. 24 Cells and media were harvested at the end of incubation and diluted with a buffer containing 0.5 ml/L NaCl, 1 mmol/L EDTA, 50 mmol/L Tris, 0.1% NP-40, 2.5% gelatin, and 0.5% BSA. Diluted media and cell lysates were first incubated with 30 g/mL of rabbit IgG at 25°C for 1 hour and then with 40 L of a 50% slurry of protein A-Sepharose for 30 minutes. Sepharose beads in the mixtures were removed by centrifugation. Resultant supernatant was incubated at 25°C for 2 hours with goat anti-human tPA IgG or rabbit anti-human PAI-1 IgG (American Diagnostica Inc). Immune complexes of tPA or PAI-1 were recovered by using protein A-Sepharose. The beads were washed sequentially with, as described above, the buffer dilution supplemented with 0.5% sodium deoxycholate followed by 10 mmol/L Tris (pH 7.5) containing 0.1% NP-40. Proteins were recovered from the beads with 125 mmol/L Tris buffer (pH 6.8) containing 20% glycerol and 4.6% SDS and then analyzed by 12% SDS-PAGE. De novo synthesized tPA or PAI-1 was detected on dried gels by autoradiography and quantified by density scanning. 
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Estimation of Cytotoxicity of Lipoproteins
Analysis of CDs
Lipids in modified or native lipoproteins were extracted in chloroform/methanol, 2:1, vol/vol. The organic phase of lipid extracts was dried under N 2 at room temperature. The lipid residue was resuspended in absolute ethanol. Absorbance of lipid extracts was measured from 220 to 330 nm against an ethanol blank by using a UV spectrophotometer and was expressed in arbitrary units. 25 The extent of peroxidation was estimated from absorbance minima at 242 and 233 nm for the quantitative analysis of CDs as previously described.
25,26
Measurement of TBARS
Lipid peroxidation in lipoproteins and the postculture media of ECs was determined by measuring the amount of TBARS and expressed as nanomoles of malondialdehyde per milligram of protein in LDL as previously described.
27,28
Measurement of Protein Concentrations in Lipoproteins and Cells
Protein contents in lipoproteins were measured by using a modified Lowry method. 29 For analyzing total proteins in cultured cells, cells were lysed in PBS containing 0.5% Triton X-100 and 0.1% SDS.
Selected Abbreviations and Acronyms
AGE ϭ advanced glycation end product CD ϭ conjugated diene (HUV)EC ϭ (human umbilical vein) endothelial cell PAGE ϭ polyacrylamide gel electrophoresis PAI-1 ϭ plasminogen activator inhibitor-1 TBARS ϭ thiobarbituric acid-reactive substances tPA ϭ tissue plasminogen activator
Statistical Analysis
Data are presented as meanϮSD. Probability between paired data was estimated with Student's t test. Comparisons among multiple groups were achieved by one-way ANOVA followed by Duncan's test. The level of significance was defined as PϽ0.05.
Results
Biochemical Characterization of Glycated LDL
The abundance of lysine in glycated LDL ( Figure 1B ) was greatly reduced compared with native LDL ( Figure 1A ). An extra amino acid peak ( Figure 1B ) was detected in glycated LDL but not in native LDL. This product comigrated with synthesized glucitollysine ( Figure 1C ), a glycation product of lysine. The glucitollysine-to-lysine ratio was elevated 3-fold in LDL glycated by 25 mmol/L glucose compared with nonglycated LDL (Table 1 ). Radioactivity of [ 14 C]glucose in glucitollysine was 5 to 6 times higher than in background, lysine, or phenylalanine. The glucitollysine-to-lysine ratio is only one of several potential markers for the pathogenic alterations in glycated LDL. Glycated LDL migrated apparently faster than did native LDL toward the positively charged anode on 1% agarose electrophoresis gel, as expected (data not shown). The levels of TBARS in glycated LDL were very low or undetectable (0.10Ϯ0.09 nmol malondialdehyde per milligram protein, meanϮSD, nϭ4), which was slightly higher than but not significantly different from that in native LDL (0.06Ϯ0.06 nmol/mg). The levels of TBARS in oxidized LDL were 46.16Ϯ3.85 nmol/mg. In the lipid extracts of native LDL, no CDs were detected. Oxidized LDL contained CDs at 233 and 242 nm ( Figure 2 ). The absorbance minimum of CDs at 233 nm in glycated LDL was significantly higher than that in oxidized LDL, but no CDs were found at 242 nm in glycated LDL (Table 2, Figure 2 ).
Effect of Glycated LDL on PAI-1 and tPA Secretion
The influence of the extent of glycation of LDL on the generation of PAI-1 and tPA was examined in HUVECs. Cells were treated with 100 g/mL of glycated LDL modified with 25 to 200 mmol/L glucose for 1 week. Glycated LDL (100 g/mL) modified by Ն50 mmol/L glucose significantly increased the levels of PAI-1 antigen in the media of HUVECs after 48 hours of treatment (6.43Ϯ0.39, 6.58Ϯ0.27, or 6.76Ϯ0.14 g/mg by 50, 100, or 200 mmol/L, respectively, of glucose-modified LDL) compared with native LDL (5.37Ϯ0.37 g/mg, nϭ4, PϽ0.01, Figure 3 , top). To evaluate the influence of the length of glycation on glycated LDLinduced PAI-1 generation, ECs were treated with 100 g/mL of glycated LDL modified by a lower concentration of glucose for a longer time (25 mmol/L glucose for 3 weeks) for 48 hours compared with glycated LDL modified by 25 mmol/L glucose for 1 week or 50 mmol/L glucose for 2 weeks. The generation of PAI-1 in ECs treated with glycated LDL modified by 25 mmol/L glucose for 3 weeks or by 50 mmol/L glucose for 2 weeks was significantly higher than in ECs treated with matching native LDL (PϽ0.01). Native LDL proceeded in parallel with glycated LDL for 3 weeks without exposure to glucose-stimulated PAI-1 production compared with control cultures (PϽ0.05), which was possi- . Derivatized amino acids in LDL were analyzed on reverse-phase high-performance liquid chromatography columns with a gradient solvent system composed of 100% to 70% of 70 mmol/L sodium acetate and 0% to 30% of acetonitrile. I indicates isoleucine; L, leucine; *, glucitollysine; F, phenylalanine; and K, lysine.
bly due to peroxidation. However, native LDLs allowed to proceed for 1 or 2 weeks under the same condition did not significantly affect PAI-1 production ( Table 3) .
The generation of tPA from HUVECs was significantly reduced by a 24-hour treatment with 100 g/mL of glycated LDL modified by 25 mmol/L glucose for 1 week (0.75Ϯ0.03 g/mg) compared with native LDL (0.84Ϯ0.06 g/mg, nϭ4, PϽ0.05, Figure 3 , bottom). The decrease in tPA generation was more evident in ECs treated with LDL modified by Ն50 mmol/L glucose for 1 week (0.48Ϯ0.06, 0.51Ϯ0.05, or 0.56Ϯ0.06 g/mg by 50, 100, or 200 mmol/L, respectively, of glucose-modified LDL) compared with native LDL (PϽ0.01).
After Ն24 hours of incubation with 100 g/mL of native LDL, the levels of PAI-1 (4.52Ϯ0.26 g/mg after 24 hours, 5.31Ϯ0.31 g/mg after 48 hours) in the media were significantly higher than in time-matched controls (3.71Ϯ0.17 g/mg after 24 hours, 4.09Ϯ0.26 g/mg after 48 hours, nϭ4, PϽ0.01). Treatment with equal amounts of glycated LDL (modified by 50 mmol/L glucose for 2 weeks) induced significantly greater increases of PAI-1 released from HUVECs (5.35Ϯ0.37 g/mg after 24 hours, 6.28Ϯ0.19 g/mg after 48 hours) compared with cells treated with native LDL for matching periods (Figure 4, top) . Dose-response curves for the effect of glycated LDL on PAI-1 generation were observed in HUVECs treated with 10 to 100 g/mL of glycated or native LDL. The levels of PAI-1 antigen in the medium of HUVECs treated with Ն50 g/mL of glycated LDL (4.66Ϯ0.25 g/mg for 50 g/mL, 5.41Ϯ0.35 g/mg for 100 g/mL) were significantly higher than those in cells treated with equal amounts of native LDL (3.37Ϯ0.22 g/mL for 50 g/mL, 4.28Ϯ0.16 g/mg for 100 g/mL, nϭ4, PϽ0.01, Figure 4 , bottom).
To answer the question whether the transcription of PAI-1 was stimulated during this process, HUVECs were treated with 0.2 g/mL of actinomycin D in addition to 100 g/mg of native or glycated LDL. 13 Actinomycin D treatment inhibited native and glycated LDL-induced PAI-1 generation from HUVECs to levels (native LDL, 5.34Ϯ0.51 g/mg versus native LDLϩactinomycin D, 4.28Ϯ0.32 g/mg, nϭ4, Values are mean of two preparations. LDL (2 mg/mL) was glycated with 5 to 200 mmol/L glucose for 1 week at 37°C. Glucitollysine and lysine in nonglycated and glycated LDLs were analyzed by high-performance liquid chromatography. Glucitollysine/lysine represents the ratio between the areas of the peaks corresponding to the two compounds. Figure 6 , top). Treatment with Ն25 g/mL of native or glycated LDL for 24 hours significantly reduced tPA secretion from HUVECs compared with no-addition controls (1.15Ϯ0.09 g/mg, PϽ0.01). The amounts of tPA secreted from ECs treated with 25 to 100 g/mL of glycated LDL (0.75Ϯ0.05, 0.58Ϯ0.02, or 0.57Ϯ0.05 g/mg by 25, 50, or 100 g/mL) were significantly less than those from cells treated with corresponding amounts of native LDL (0.90Ϯ0.04, 0.71Ϯ0.04, or 0.67Ϯ0.04 g/mg by 25, 50, or 100 g/mL, PϽ0.05, Figure 6 , bottom).
Effect of Glycated LDL on PAI-1 and tPA mRNA
PAI-1 mRNA in HUVECs was present as two distinguishable species, Ϸ3.4 and 2.4 kb, as previously described. 13 Treatment with 100 g/mL of native LDL for 48 hours increased the level of 2.4-kb PAI-1 mRNA by 2-fold (PϽ0.001) but slightly reduced the level of 3.4-kb PAI-1 mRNA. Treatment with an equal amount of glycated LDL evidently augmented the level of 2.4-kb PAI-1 mRNA compared with controls and native LDL-treated cells (Figure 7, top) . The levels of 2.4-kb PAI-1 mRNA in glycated LDL-treated ECs were Ͼ3.25Ϯ0.21-fold higher than the mean of controls and were significantly greater than that in native LDL-treated cells (2.13Ϯ0.16-fold, nϭ3, PϽ0.001, Figure 7 , bottom). This finding is consistent with the inhibitory effect of actinomycin D on glycated LDL-induced PAI-1 generation ( Figure 5 ). However, the level of tPA mRNA in HUVECs treated with 100 g/mL of glycated or native LDL did not significantly differ from controls ( Figure 8 ).
Effect of Glycated LDL on De Novo Synthesis of tPA and PAI-1
To determine whether the synthesis of fibrinolytic regulators was altered by glycated LDL treatment, HUVECs were metabolically labeled with [ 35 S]methionine/cystine in the presence of native or glycated LDL. De novo synthesized PAI-1 was mainly detected in the cell-associated pool of HUVECs. Radioactivity of PAI-1 was weak in the medium and not visualized by using autoradiography. Native LDL (100 g/mL for 48 hours) moderately increased the level of de novo synthesized PAI-1 in the cell-associated compartment (3.47Ϯ0.9-fold) compared with controls (1.00Ϯ0.07-fold of the mean, nϭ4, PϽ0.05). Treatment with glycated LDL significantly increased the level of de novo synthesized PAI-1 (13.95Ϯ4.2-fold) compared with native LDL (nϭ4, PϽ0.05, Figure 9 ). De novo synthesized tPA was mainly found in the media of HUVECs. Treatment with 100 g/mL of native LDL reduced tPA synthesis after 24 hours of incubation. Glycated LDL at the same concentration further attenuated tPA synthesis in HUVECs compared with native LDL (PϽ0.01, Figure 10 ).
Effects of Oxidized and Aminoguanidine-Treated Glycated LDL on the Generation of PAI-1 and tPA
In the media of HUVECs treated with 100 g/mL of oxidized LDL for 48 hours, the levels of PAI-1 were 23% higher than in Northern analysis was performed as described in the legend to Figure 7 . Corrected levels of tPA mRNA were presented after adjustment with respect to levels of ␤-actin mRNA. Values are fold increase of the mean of controls (meanϮSD, nϭ3).
native LDL-treated cells and 51% higher than controls (PϽ0.001) but did not significantly differ from those of cells treated with glycated LDL. The generation of tPA in oxidized LDL-treated ECs was 35% lower than that from native LDLtreated cells (PϽ0.001) and 17% less than in glycated LDLtreated ECs (PϽ0.05, Figure 11 ).
Aminoguanidine is an antioxidant and an inhibitor for the formation of AGEs. 30, 31 Addition of 25 mmol/L aminoguanidine during LDL glycation effectively inhibited the glycation of lysine ( Figure 1C) . The inhibitory effect of aminoguanidine on the glycation of lysine was evident in LDLs treated with Ն25 mmol/L aminoguanidine (data not shown). Glycated LDL-induced changes in the secretion of PAI-1 and tPA antigen (PAI-1, 148.5Ϯ5.3%; tPA, 52.8Ϯ5.2% of control) were effectively reduced by treatment with 25 mmol/L aminoguanidine during glycation (PAI-1, 122.7Ϯ7.9%; tPA, 72.0Ϯ5.3% of control, PϽ0.01) to levels that were not significantly different from those of native LDL-treated cells (PAI-1, 122.5Ϯ3.6%; tPA, 66.4Ϯ3.5% of control, Figure 11 ). Additionally, aminoguanidine treatment normalized the de novo synthesis of PAI-1 and tPA in ECs induced by glycated LDL (Figures 9 and 10) .
Discussion
Attenuation of fibrinolytic activity has been frequently found in diabetic patients and has been implicated in the development of cardiovascular complications in diabetes. 32, 33 Alternations in the generation of PAI-1 and tPA from vascular ECs may directly affect fibrinolytic activity in the blood circulation. The results of the present studies demonstrate that glycation enhances the production of PAI-1 and reduces the generation of tPA induced by LDL in cultured vascular ECs. Increased generation of PAI-1 accompanied by a decreased release of tPA from vascular ECs may result in hypofibrinolysis and lead to intravascular thrombogenesis. The findings of the present study may help investigators understand the mechanism for attenuated fibrinolytic activity and increased thrombotic vascular complications in diabetes. It should be pointed out that the present study only examined the effects of LDL and its glycated form from healthy individuals. The composition of LDL in diabetes may differ from that from nondiabetic subjects with respect to factors other than glycation products. Investigation of the effects of LDL from various types of diabetic individuals may provide additional information on the modulation of EC-derived fibrinolytic regulators in diabetes.
The results of the present study indicate that the generation of PAI-1 and tPA in ECs is significantly altered by glycated LDL that has been modified by 25 to 50 mmol/L glucose for extended periods. This range of blood glucose occurs in uncontrolled diabetes. Previous studies reported that the levels of glucose may be elevated to a range of 200 to 2000 mg/dL (11 to 111 mmol/L) in patients with diabetic ketoacidosis. 34 The extent of glycation of plasma proteins is correlated with the length of glycation time as well as glucose concentrations. 35 This concept is supported by the results of the present study that LDL glycated by 25 mmol/L glucose for 3 weeks significantly increased PAI-1 generation compared with LDL glycated by the same concentration of glucose for a shorter period (1 week). We speculate that the generation of PAI-1 may be increased by LDL modified by even lower concentrations of glucose for longer periods in vivo.
Levin et al 14 described that the generation of tPA from HUVECs was reduced by treatment with native LDL. The effect of native LDL on the secretion of tPA from HUVECs observed in the present study supports their observation. The level of tPA mRNA was inhibited by LDL in HUVECs in medium with the addition of 100 g/mL of heparin in the previous study.
14 It has been shown that Ն50 g/mL of heparin effectively inhibits the levels of tPA mRNA in baboon aortic smooth muscle cells. 36 In the present study, heparin was supplemented only in the growth medium but not in the stimulation medium to avoid interference with the regulation of tPA generation. Pilot studies in our laboratory have found that treatment with Ն200 g/mL of native or glycated LDL in heparin-free medium evidently impairs [ 3 H]leucine incorporation into HUVECs (data not shown). Glycated LDL did not reduce the mRNA level of tPA mRNA but did inhibit the synthesis of tPA in ECs. The difference between the effects of LDL on tPA mRNA in the present and the previous study 14 is likely due to the variation in stimulation conditions. The present study demonstrates that glycated LDL stimulates the steady-state levels of PAI-1 mRNA in ECs that are associated with increases in de novo synthesis and secretion of PAI-1. Actinomycin D, a known inhibitor of transcription, blocked glycated and native LDL-induced generation of PAI-1. The combination of these findings strongly suggests that both glycated and native LDL regulate PAI-1 production in ECs at the transcriptional level. In contrast, the steady-state level of tPA mRNA in ECs was not affected by glycated or native LDL. De novo synthesis of tPA was reduced in native and glycated LDL-treated ECs. Therefore, the reduction in tPA generation from ECs induced by native and glycated LDL may result from the decrease in tPA synthesis or secretion.
Previous studies have demonstrated that oxidized LDL stimulates the generation of PAI-1 in ECs. 10, 11, 13 The results of the present study indicate that oxidized LDL also reduces tPA generation in HUVECs. Glycated LDL may be more susceptible to oxidation than is native LDL. 9 Although the TBARS assay did not reveal a significant increase in peroxidation in glycated LDL, CDs were detected at 233 nm in lipid extracts of glycated LDL in our studies. The pattern of CDs in glycated LDL apparently differs from that in oxidized LDL (Figure 2 ). The findings suggest the presence of excess lipid peroxidation products in glycated LDL, and glycoxidation may be a major contributing factor for glycated LDL-induced alterations in PAI-1 and tPA generation in ECs.
Extended glycation induces the generation of AGEs in blood components and tissues. AGEs promote cross-linking between glycation products and arterial wall proteins, which may be involved in atherogenesis. 37 AGE complexes also enable the generation of reactive oxygen intermediates. 38 Receptors for AGEs have been identified in several types of cells, including ECs. 39 Aminoguanidine inhibits the formation of AGEs by forming a complex with early glycation products. 31 Treatment with aminoguanidine has prevented the formation of AGEs in the aortic wall of diabetic rats. 37 The results of the present study for the first time demonstrate that treatment with aminoguanidine during glycation normalized glycated LDL-induced overproduction of PAI-1 and the reduction of tPA synthesis in HUVECs. Aminoguanidine is also an inhibitor of NO synthesis 40 and diamine oxidase. 41 Previous studies indicated that treatment with aminoguanidine prevented the oxidation of LDL. 42 Both AGEs and oxidation may contribute to glycated LDL-induced generation of fibrinolytic regulators in vascular ECs, and the levels of AGEs are higher in both apoB and the lipid moiety of LDLs isolated from diabetic patients than from nondiabetic subjects. 43 Determination of interactions between AGEs, LDL-specific structure, and the EC surface may help investigators define the regulatory mechanism for glycated LDL-induced alterations in the generation of fibrinolytic regulators from ECs.
The present study was performed in ECs isolated from umbilical veins. Previous studies have demonstrated that HUVECs are functionally closer to arterial ECs than to ECs isolated from other veins. 44 This is possibly due to the unique circumstance of the umbilical vein, which carries oxygenated and nutrient-bearing blood instead of regular venous blood from the placenta to fetus. It is reasonable, therefore, to predict that HUVECs may respond to glycated LDL in a way similar to arterial ECs than do other venous ECs.
In summary, glycation enhances the overproduction of PAI-1 and further reduces the generation of tPA induced by LDL in vascular ECs. The effect of glycated LDL on the generation of PAI-1 and tPA was effectively prevented by treatment with aminoguanidine. Our findings suggest that increased levels of glycated LDL in the blood circulation may attenuate fibrinolytic activity. Management of hyperglycemia and hyperbetalipoproteinemia or the reduction of glycation of lipoproteins through pharmacological intervention potentially prevents the development of thrombotic vascular complications in diabetic subjects.
